New York, NY, USA
Emendo develops biotherapeutics, which are based on its novel gene editing tools. Leveraging our expertise in protein engineering, we utilize both random and rational methodologies to re-design genome editing tools, such as CRISPR associated protein 9 (Cas9), Transcription activator-like effector nuclease (TALEN) and Zinc fingers (ZFNs). We improve the safety and efficacy of our therapeutic agent, overcoming some of the major challenges in gene editing today: enhancing homology direct repair (HDR), reducing non-homologous end joining (NHEJ), increasing specificity and reducing off-target effect. Meeting these challenges opens new areas of therapeutics thus far unavailable due to inherent limitations. Founded by experienced entrepreneurs, leading scientists and executive managers, Emendo combines a highly innovative "out of the box" approach with a practical product oriented approach.Inaccurate data? Flag it here.